Cases & Deals

Odyssey Thera raises capital in Series A-2 round

Clients Odyssey Thera, Inc.

Jones Day represented Odyssey Thera, Inc., a privately held biotechnology company, in connection with its issuance of Series A-2 Preferred Stock in private placement to Merck & Co., Inc. and previous investors HBM Partners, Burrill & Company, and Lonza.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.